Marinus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.78
- Today's High:
- $7.03
- Open Price:
- $6.82
- 52W Low:
- $3.465
- 52W High:
- $11.15
- Prev. Close:
- $6.82
- Volume:
- 209485
Company Statistics
- Market Cap.:
- $345.16 million
- Book Value:
- 1.133
- Revenue TTM:
- $25.96 million
- Operating Margin TTM:
- -476.5%
- Gross Profit TTM:
- $-55943000
- Profit Margin:
- -106.64%
- Return on Assets TTM:
- -49.79%
- Return on Equity TTM:
- -89.11%
Company Profile
Marinus Pharmaceuticals Inc had its IPO on 2014-07-31 under the ticker symbol MRNS.
The company operates in the Healthcare sector and Biotechnology industry. Marinus Pharmaceuticals Inc has a staff strength of 151 employees.
Stock update
Shares of Marinus Pharmaceuticals Inc opened at $6.82 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.78 - $7.03, and closed at $6.98.
This is a +2.35% increase from the previous day's closing price.
A total volume of 209,485 shares were traded at the close of the day’s session.
In the last one week, shares of Marinus Pharmaceuticals Inc have slipped by -7.18%.
Marinus Pharmaceuticals Inc's Key Ratios
Marinus Pharmaceuticals Inc has a market cap of $345.16 million, indicating a price to book ratio of 2.654 and a price to sales ratio of 10.2057.
In the last 12-months Marinus Pharmaceuticals Inc’s revenue was $25.96 million with a gross profit of $-55943000 and an EBITDA of $-119317000. The EBITDA ratio measures Marinus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Marinus Pharmaceuticals Inc’s operating margin was -476.5% while its return on assets stood at -49.79% with a return of equity of -89.11%.
In Q2, Marinus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 239.7%.
Marinus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Marinus Pharmaceuticals Inc’s profitability.
Marinus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 5.828 and a EV to EBITDA ratio of -37.3759. Its price to sales ratio in the trailing 12-months stood at 10.2057.
Marinus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $201.20 million
- Total Liabilities
- $25.60 million
- Operating Cash Flow
- $5.00 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Marinus Pharmaceuticals Inc ended 2024 with $201.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $201.20 million while shareholder equity stood at $57.34 million.
Marinus Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $25.60 million in other current liabilities, 51000.00 in common stock, $-497185000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $127.79 million and cash and short-term investments were $175.34 million. The company’s total short-term debt was $4,531,000 while long-term debt stood at $68.14 million.
Marinus Pharmaceuticals Inc’s total current assets stands at $194.61 million while long-term investments were $0 and short-term investments were $47.55 million. Its net receivables were $5.23 million compared to accounts payable of $2.30 million and inventory worth $2.67 million.
In 2024, Marinus Pharmaceuticals Inc's operating cash flow was $5.00 million while its capital expenditure stood at $0.
Comparatively, Marinus Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.98
- 52-Week High
- $11.15
- 52-Week Low
- $3.465
- Analyst Target Price
- $23.6
Marinus Pharmaceuticals Inc stock is currently trading at $6.98 per share. It touched a 52-week high of $11.15 and a 52-week low of $11.15. Analysts tracking the stock have a 12-month average target price of $23.6.
Its 50-day moving average was $8.64 and 200-day moving average was $7.3 The short ratio stood at 5.26 indicating a short percent outstanding of 0%.
Around 77.9% of the company’s stock are held by insiders while 8641.2% are held by institutions.
Frequently Asked Questions About Marinus Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.